Table 7 Sensitivity analysis in a health economic model of a cohort of IMSS T1D adult patients to determine the ICER of CSII therapy compared to MDI therapy
ICER (MXN/QALY) | ICER (USD/QALY) | CSII | MDI | |||||
|---|---|---|---|---|---|---|---|---|
Total costs (MXN) | Total costs (USD) | QALY | Total costs (MXN) | Total costs (USD) | QALY | |||
Base case (direct costs) | 478,020 | 25,993 | 1,404,173 | 76,355 | 7.052 | 1,110,573 | 60,390 | 6.438 |
Secondary case (direct and indirect costs) | 369,593 | 20,097 | 1,832,057 | 99,622 | 7.052 | 1,605,053 | 87,279 | 6.438 |
50% reduction in HbA1c benefit (− 0.6%) | 903,984 | 49,156 | 1,404,910 | 76,395 | 6.764 | 1,110,573 | 60,390 | 6.438 |
Disc rate: 3% costs + 0% benefits | 216,246 | 11,759 | 1,831,524 | 99,593 | 13.266 | 1,441,026 | 78,359 | 11.46 |
Disc rate: 7% costs + 7% benefits | 533,083 | 28,988 | 1,123,780 | 61,108 | 5.836 | 890,663 | 48,432 | 5.399 |
Subgroup HbA1c ≤ 9% | 1,334,460 | 72,564 | 1,403,917 | 76,341 | 7.436 | 1,056,824 | 57,467 | 7.176 |
Subgroup HbA1c > 9% | 262,237 | 14,260 | 1,360,833 | 73,999 | 6.633 | 1,069,567 | 58,160 | 5.522 |
Subgroup ≤ 10 years | 537,432 | 29,224 | 1,271,697 | 69,152 | 7.993 | 928,010 | 50,463 | 7.354 |
Subgroup > 10 years | 1,376,224 | 74,835 | 1,022,134 | 55,581 | 3.249 | 814,737 | 44,303 | 3.098 |